Starlix nateglinide: Phase III data; NDA under review

NOVN published in Diabetes Care an analysis of subgroup data from its 24-week, 701-patient U.S. Phase III trial of Starlix. Among 197 patients not previously treated with oral hypoglycemic agents, bot...